Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: A systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data

E.A. Ashley, F. Aweeka, K.I. Barnes, Q. Bassat, S. Borrmann, Timothy Davis, P. Deloron, M.B. Denis, A.A. Djimde, J.F. Faucher, B. Genton, P.J. Guérin, K. Hamed, E.M. Hodel, L. Huang, V. Jullien, H.A. Karunajeewa, J.R. Kiechel, P.E. Kofoed, G. LefèvreN. Lindegardh, K. Marsh, A. Mårtensson, M. Mayxay, R. Mcgready, C. Moreira, P.N. Newton, B.E. Ngasala, F. Nosten, C. Nsanzabana, S. Parikh, R.N. Price, P. Ringwald, L. Rombo, B. Schramm, C.H. Sibley, K. Stepniewska, J. Ursing, M.V. Vugt, N.J. White, L.J. Workman, P Dahal

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    © 2015 WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group. Background: Achieving adequate antimalarial drug exposure is essential for curing malaria. Day 7 blood or plasma lumefantrine concentrations provide a simple measure of drug exposure that correlates well with artemether-lumefantrine efficacy. However, the 'therapeutic' day 7 lumefantrine concentration threshold needs to be defined better, particularly for important patient and parasite sub-populations. Methods: The WorldWide Antimalarial Resistance Network (WWARN) conducted a large pooled analysis of individual pharmacokinetic-pharmacodynamic data from patients treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria, to define therapeutic day 7 lumefantrine concentrations and identify patient factors that substantially alter these concentrations. A systematic review of PubMed, Embase, Google Scholar, ClinicalTrials.gov and conference proceedings identified all relevant studies. Risk of bias in individual studies was evaluated based on study design, methodology and missing data. Results: Of 31 studies identified through a systematic review, 26 studies were shared with WWARN and 21 studies with 2,787 patients were included. Recrudescence was associated with low day 7 lumefantrine concentrations (HR 1.59 (95 % CI 1.36 to 1.85) per halving of day 7 concentrations) and high baseline parasitemia (HR 1.87 (95 % CI 1.22 to 2.87) per 10-fold increase). Adjusted for mg/kg dose, day 7 concentrations were lowest in very young children (98 % cure rates (if parasitemia
    Original languageEnglish
    Pages (from-to)1-19
    JournalBMC Medicine
    Volume13
    Issue number1
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: A systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data'. Together they form a unique fingerprint.

  • Cite this

    Ashley, E. A., Aweeka, F., Barnes, K. I., Bassat, Q., Borrmann, S., Davis, T., Deloron, P., Denis, M. B., Djimde, A. A., Faucher, J. F., Genton, B., Guérin, P. J., Hamed, K., Hodel, E. M., Huang, L., Jullien, V., Karunajeewa, H. A., Kiechel, J. R., Kofoed, P. E., ... Dahal, P. (2015). Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: A systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Medicine, 13(1), 1-19. https://doi.org/10.1186/s12916-015-0456-7